David Kudrow

4.2k total citations · 3 hit papers
65 papers, 2.8k citations indexed

About

David Kudrow is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, David Kudrow has authored 65 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Psychiatry and Mental health, 27 papers in Pathology and Forensic Medicine and 15 papers in Physiology. Recurrent topics in David Kudrow's work include Migraine and Headache Studies (58 papers), Trigeminal Neuralgia and Treatments (24 papers) and Sympathectomy and Hyperhidrosis Treatments (10 papers). David Kudrow is often cited by papers focused on Migraine and Headache Studies (58 papers), Trigeminal Neuralgia and Treatments (24 papers) and Sympathectomy and Hyperhidrosis Treatments (10 papers). David Kudrow collaborates with scholars based in United States, Germany and Denmark. David Kudrow's co-authors include Jan Lewis Brandes, Lee Kudrow, David W. Dodick, Messoud Ashina, Richard B. Lipton, Daniel D. Mikol, Hernàn Picard, Stephen D. Silberstein, Peter J. Goadsby and Robert Croop and has published in prestigious journals such as The Lancet, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

David Kudrow

61 papers receiving 2.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

2018 423 citations David W. Dodick, Messoud Ashina et al. Cephalalgia profile →
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial

2014 299 citations David W. Dodick, Peter J. Goadsby et al. profile →
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

2020 233 citations Robert Croop, Richard B. Lipton et al. The Lancet profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
David Kudrow	2.5k	1.8k	1.1k	298	275	65	2.8k
Jessica Ailani	2.9k 1.2×	1.8k 1.0×	1.0k 1.0×	378 1.3×	388 1.4×	120	3.3k
Stephen D. Silberstein	2.9k 1.2×	1.7k 1.0×	1.1k 1.0×	307 1.0×	237 0.9×	58	3.2k
Frederick G. Freitag	3.0k 1.2×	1.8k 1.0×	1.2k 1.1×	239 0.8×	266 1.0×	65	3.3k
ME Bigal	2.4k 1.0×	1.4k 0.8×	906 0.8×	291 1.0×	342 1.2×	46	2.8k
Sheena K. Aurora	1.7k 0.7×	946 0.5×	761 0.7×	240 0.8×	292 1.1×	48	1.9k
Todd D. Rozen	1.9k 0.8×	1.3k 0.7×	913 0.8×	140 0.5×	547 2.0×	124	2.4k
Derya Uludüz	1.6k 0.6×	792 0.4×	434 0.4×	219 0.7×	275 1.0×	83	2.0k
Thien Phu	1.6k 0.6×	705 0.4×	462 0.4×	222 0.7×	280 1.0×	43	1.9k
Marek Gawel	1.6k 0.6×	904 0.5×	786 0.7×	316 1.1×	819 3.0×	75	2.8k
Anish Bahra	2.5k 1.0×	2.0k 1.1×	1.4k 1.3×	146 0.5×	238 0.9×	38	2.7k

Countries citing papers authored by David Kudrow

Since Specialization

Citations

This map shows the geographic impact of David Kudrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kudrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kudrow more than expected).

Fields of papers citing papers by David Kudrow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kudrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kudrow. The network helps show where David Kudrow may publish in the future.

Co-authorship network of co-authors of David Kudrow

This figure shows the co-authorship network connecting the top 25 collaborators of David Kudrow. A scholar is included among the top collaborators of David Kudrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Kudrow. David Kudrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kudrow, David, Robert Croop, Alexandra Thiry, & Richard Lipton. (2025). A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache The Journal of Head and Face Pain. 66(2). 407–416. 4 indexed citations

Croop, Robert, Gary Berman, David Kudrow, et al.. (2024). A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 44(4). 2225278000–2225278000. 22 indexed citations

Kudrow, David, Susan Hutchinson, Glenn C. Pixton, & Terence Fullerton. (2024). Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study. Pain and Therapy. 14(1). 237–255. 1 indexed citations

Tepper, Stewart J., Richard B. Lipton, Stephen D. Silberstein, et al.. (2023). Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache The Journal of Head and Face Pain. 63(6). 730–742. 5 indexed citations

Kudrow, David, Rima M. Dafer, David W. Dodick, et al.. (2023). Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data. Headache The Journal of Head and Face Pain. 63(3). 418–428. 12 indexed citations

Lipton, Richard B., David W. Dodick, David Kudrow, et al.. (2021). Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies. Cephalalgia. 41(14). 1458–1466. 4 indexed citations

Kudrow, David, Kathleen Mullin, Gary Berman, et al.. (2021). Long-term Use of Rimegepant 75 mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics (5072). Neurology. 96(15_supplement). 2 indexed citations

Kudrow, David, Roger Cady, Brent Allan, et al.. (2021). Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurology. 21(1). 126–126. 63 indexed citations

McAllister, Peter, Gary Berman, David Kudrow, et al.. (2020). Rimegepant 75 mg Demonstrates Superiority to Placebo on Nausea Freedom: Results from a Post Hoc Pooled Analysis of 3 Phase 3 Trials in the Acute Treatment of Migraine (2402). Neurology. 94(15_supplement). 1 indexed citations

10.

Bangs, Mark E., David Kudrow, Shufang Wang, et al.. (2020). Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurology. 20(1). 25–25. 38 indexed citations

11.

Croop, Robert, Richard B. Lipton, David Kudrow, et al.. (2020). Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet. 397(10268). 51–60. 233 indexed citations breakdown →

12.

Reuter, Uwe, Todd J. Schwedt, David Kudrow, et al.. (2019). Long-term efficacy of erenumab in patients with episodic migraine who have failed prior preventive migraine therapies. European Journal of Neurology. 26. 637–637. 2 indexed citations

13.

Brandes, Jan Lewis, David Kudrow, Suzanne Klise, et al.. (2019). Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR) (P1.10-021). Neurology. 92(15_supplement). 2 indexed citations

14.

Tepper, Stewart J., et al.. (2019). PND80 RAPID MIGRAINE RESPONSE BY MONTH 1 AND CLINICALLY MEANINGFUL IMPROVEMENTS IN HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH MIGRAINE IN PHASE 3 TRIALS OF EPTINEZUMAB. Value in Health. 22. S285–S285. 1 indexed citations

15.

Winner, Paul, Uwe Reuter, David W. Dodick, et al.. (2018). Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors (P4.100). Neurology. 90(15_supplement). 1 indexed citations

16.

Schwedt, Todd J., Uwe Reuter, Stewart J. Tepper, et al.. (2018). Early onset of efficacy with erenumab in patients with episodic and chronic migraine. The Journal of Headache and Pain. 19(1). 92–92. 72 indexed citations

17.

Camporeale, Angelo, David Kudrow, Shufang Wang, et al.. (2018). A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurology. 18(1). 188–188. 105 indexed citations

18.

Brandes, Jan Lewis, David Kudrow, John F. Rothrock, et al.. (2006). Assessing the Ability of Topiramate to Improve the Daily Activities of Patients With Migraine. Mayo Clinic Proceedings. 81(10). 1311–1319. 31 indexed citations

19.

Silberstein, Stephen D., Frederick G. Freitag, Todd D. Rozen, et al.. (2005). Tramadol/Acetaminophen for the Treatment of Acute Migraine Pain: Findings of a Randomized, Placebo‐Controlled Trial. Headache The Journal of Head and Face Pain. 45(10). 1317–1327. 35 indexed citations

20.

Kudrow, Lee, David Kudrow, & J. Sandweiss. (1995). Rapid and Sustained Relief of Migraine Attacks With Intranasal Lidocaine: Preliminary Findings. Headache The Journal of Head and Face Pain. 35(2). 79–82. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact